Sign up to save your podcasts
Or
Share AMD 2023 Mar: Avacincaptad Pegol for Geographic Atrophy: GATHER1 18-Month Results
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AMD 2023 Mar: Avacincaptad Pegol for Geographic Atrophy: GATHER1 18-Month Results
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 Dec;37(17):3551-3557. doi: 10.1038/s41433-023-02497-w. Epub 2023 Mar 24. Erratum in: Eye (Lond). 2023 Dec;37(17):3705. doi: 10.1038/s41433-023-02548-2. PMID: 36964259; PMCID: PMC10686386.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10686386/pdf/41433_2023_Article_2497.pdf
View all episodes
By Dr Michael Nelson, OD FAAOAvacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 Dec;37(17):3551-3557. doi: 10.1038/s41433-023-02497-w. Epub 2023 Mar 24. Erratum in: Eye (Lond). 2023 Dec;37(17):3705. doi: 10.1038/s41433-023-02548-2. PMID: 36964259; PMCID: PMC10686386.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10686386/pdf/41433_2023_Article_2497.pdf